前列腺特异性膜抗原配体用于显像与治疗
本综述总结低分子量前列腺特异性膜抗原(PSMA)配体在PET显像与放射配体治疗中的临床应用。主要基于回顾性队列研究显示,PSMA配体PET在生化复发和原发前列腺癌淋巴结转移检测中具有较高价值,177Lu-PSMA放射配体治疗在前列腺特异性抗原反应率超过50%方面表现出合理应答,且3级和4级毒性极小。
要点
- PSMA配体PET在生化复发中检出率高,即使前列腺特异性抗原水平较低亦可检出。
- 原发前列腺癌中,PSMA配体PET检测转移性淋巴结优于横断面显像。
- 177Lu-PSMA放射配体治疗前列腺特异性抗原反应率超过50%,3级和4级毒性极小。
核心结论
- PSMA配体PET显像在生化复发和原发前列腺癌中具有较高价值,177Lu-PSMA放射配体治疗应答合理且安全性高,可能扩展转移性去势抵抗性前列腺癌的治疗选择。
研究设计与样本
- 本综述旨在全面概述低分子量PSMA配体用于PET显像和治疗方法的当前文献,重点关注已在临床采用的药物。
主要发现
- 主要基于回顾性队列研究显示,PSMA配体PET在生化复发中检出率高,即使前列腺特异性抗原水平较低亦可检出。
- PSMA配体PET显像在原发前列腺癌中检测转移性淋巴结优于横断面显像。
- PSMA配体PET显像在生化复发和原发疾病中均报告了相当比例的治疗管理变更。
- 177Lu-PSMA放射配体治疗显示合理应答,主要定义为前列腺特异性抗原反应超过50%,与其他近期引入的药物相当。
- 177Lu-PSMA放射配体治疗安全性高,迄今仅报告极小比例的3级和4级毒性。
关键数值与推荐
- 177Lu-PSMA放射配体治疗应答主要定义为前列腺特异性抗原反应超过50%。
- 177Lu-PSMA放射配体治疗迄今仅报告极小比例的3级和4级毒性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prostate-specific membrane antigen (PSMA) is highly expressed on most prostate cancer (PC) cells. Therefore, the targeting of PSMA has become increasingly important over the last decade. Glu-urea-based PSMA ligands used for both imaging and radioligand therapy are the mainstays of the current success. For PET imaging, both 68Ga- and 18F-labeled agents have been successfully translated to clinical applications. Mainly retrospective cohort studies have shown a high value in the setting of biochemical recurrence, with high detection rates even in the presence of low prostate-specific antigen levels. Preliminary data indicated that radioguided surgery with PSMA ligands may help to further improve patient outcomes because it facilitates the removal of small tumor deposits that are otherwise difficult to detect. For primary PC, PSMA ligand PET imaging has been shown to be superior to cross-sectional imaging for the detection of metastatic lymph nodes. In addition, it promises to also provide intraprostatic tumor localization, especially when used in combination with multiparametric MRI. Increasing numbers of studies have reported considerable changes in management resulting from PSMA ligand PET imaging for both biochemical recurrence and primary disease. The use of 177Lu-PSMA-based radioligand therapy has demonstrated a reasonable response, mainly as defined by a prostate-specific antigen response of more than 50%, comparable to other recently introduced agents. Especially given the high level of safety of 177Lu-PSMA radioligand therapy, with only minimal grade 3 and 4 toxicities reported so far, it has the potential to expand options for metastatic castration-resistant PC. This review is intended to provide a comprehensive overview of the current literature on low-molecular-weight PSMA ligands for both PET imaging and therapeutic approaches, with a focus on agents that have been clinically adopted.
引用
- Eiber M, Fendler WP, Rowe SP, et al. Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. J Nucl Med. 2017. PMID: 28864615. doi:10.2967/jnumed.116.186767
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。